Neuro

Evolution Optiks Successfully Completes Data Collection in Clinical Study of Neuro-Optical Testing Device

Retrieved on: 
Tuesday, December 5, 2023
Medicine, Brain, Safety, Decon, Head, Optometry, Patient, DSM-IV codes, Binocular vision, FDA, Neuro, Advertising, Data collection, Rehabilitation, US FDA, Diagnosis, Trial of the century, Accident

CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.

Key Points: 
  • CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.
  • The study findings will be included in the application to the FDA to support the request for approval which the company currently expects to obtain in the first quarter of 2024.
  • "The results are very promising and we look forward to sharing the final analysis with the neuro-ophthalmological community."
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Evolution Optiks Successfully Completes Data Collection in Clinical Study of Neuro-Optical Testing Device

Retrieved on: 
Tuesday, December 5, 2023
Medicine, Brain, Safety, Decon, Head, Optometry, Patient, DSM-IV codes, Binocular vision, FDA, Neuro, Advertising, Data collection, Rehabilitation, US FDA, Diagnosis, Trial of the century, Accident

CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.

Key Points: 
  • CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.
  • The study findings will be included in the application to the FDA to support the request for approval which the company currently expects to obtain in the first quarter of 2024.
  • "The results are very promising and we look forward to sharing the final analysis with the neuro-ophthalmological community."
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Rhaeos, Inc. Strengthens Leadership Team with Appointment of Dr. David Limbrick as Chief Medical Officer

Retrieved on: 
Tuesday, November 28, 2023
CNS, Principal, Research, Chicago Innovation Awards, Neuroimaging, Northwestern University, Neurosurgical anesthesia, Public service, Accreditation, Chiari malformation, Humanism, Patient, Accreditation Council, Virginia Commonwealth University, Congress of Neurological Surgeons, FDA, Neuro, Hydrocephalus, CMO, Doctor of Philosophy, Congress, Skin, Quality of life, Pediatric neurosurgery, Veterinary medicine, Medical device, Medicine, MD, Chiari, Neurosurgery

EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).

Key Points: 
  • EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).
  • Dr. Limbrick is currently a Professor at Virginia Commonwealth University, where he joined as the Chair of the Department of Neurosurgery in 2023.
  • "I am very excited to join the Rhaeos team after collaborating closely with them for the past two years," stated Dr. Limbrick.
  • The company looks forward to the continued advancement of their mission to have a global impact on neurosurgery and hydrocephalus management.

New report unveils groundbreaking opportunities for U.S. health care transformation

Retrieved on: 
Monday, November 27, 2023
Medicine, Artificial intelligence, Health equity, Health policy, Bionics, Head, Proteomics, Disease, Epigenomics, Genomics, Patient, Buffalo Center, Iowa, Social, Intelligence, Neuro, Biomedical sciences, Methodism, Neurosurgery, MBA, MD, University, Cancer, Future, CMO, Doctor of Philosophy, AI, Attention span, Medical device, Management, Dentistry, Buffalo, Health

BUFFALO, N.Y., Nov. 27, 2023 /PRNewswire/ -- "The Future of Health" — a forward-looking report jointly released by the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and the Jacobs Institute, a nonprofit medical device innovation center — heralds massive potential for improving health care in the United States.

Key Points: 
  • While acknowledging systemic challenges, the report shines a spotlight on advancements and opportunities that promise to revolutionize health care.
  • The report is a follow-up to the 2017 The Future of Medicine report, which forecast disruptive changes wrought by emerging technologies and social movements on the health care landscape.
  • Life-extension science: Groundbreaking research is promising not just longer lives, but also late-in-life years filled with health, fulfillment and productivity.
  • Personal health technology: Cutting-edge devices and AI technologies are putting the power of health monitoring into the hands of individuals, enabling early action to prevent illness.

Pixyl receives FDA clearance for AI-powered brain MRI software Pixyl.Neuro™

Retrieved on: 
Monday, November 20, 2023
Radiology, Brain, Medical Device Regulation Act, Alzheimer's disease, Personalized medicine, Disease, DSM-IV codes, Neuro, European, Division, FDA, Neuroradiology, Atrophy, Diagnosis, MRI, University of California, Davis, Certification, Health, UC, Medical device, Medical imaging

GRENOBLE, France, Nov. 20, 2023 /PRNewswire/ -- Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro™, the next-generation AI software for brain MRI analysis that recently demonstrated enhanced detection rates up to 28%1.

Key Points: 
  • GRENOBLE, France, Nov. 20, 2023 /PRNewswire/ -- Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro™, the next-generation AI software for brain MRI analysis that recently demonstrated enhanced detection rates up to 28%1.
  • Pixyl is an award-winning French medtech specializing in AI-powered MRI solutions to improve patient care.
  • "AI-driven MRI analysis opens the possibility of accessing previously unavailable clinically-relevant information to reinforce radiology workflows, especially in the context of neurological disorders."
  • We chose Pixyl to answer our routine practice needs based on their track-record of delivering high-quality brain MRI solutions.

TSI Group Joins Halma Group, Unveiling New Avenues for Growth

Retrieved on: 
Monday, November 20, 2023
Organization, Health, Spine, Cardiothoracic surgery, Partnership, Growth, Iron ore, Neuro

Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.

Key Points: 
  • Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.
  • "This is an exciting development for the TSI Group, supporting our ambitions to expand and develop globally," says Danny Fishman, President at the TSI Group.
  • Leveraging Halma's expansive network of resources and focus on operational excellence, the TSI Group anticipates numerous new opportunities on the horizon.
  • The union of the TSI Group with Halma marks a pivotal moment for both organizations, creating a synergy that positions the TSI Group for sustained success and innovation in the dynamic field of medical technology.

TSI Group Joins Halma Group, Unveiling New Avenues for Growth

Retrieved on: 
Monday, November 20, 2023
Organization, Health, Spine, Cardiothoracic surgery, Partnership, Growth, Iron ore, Neuro

Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.

Key Points: 
  • Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.
  • "This is an exciting development for the TSI Group, supporting our ambitions to expand and develop globally," says Danny Fishman, President at the TSI Group.
  • Leveraging Halma's expansive network of resources and focus on operational excellence, the TSI Group anticipates numerous new opportunities on the horizon.
  • The union of the TSI Group with Halma marks a pivotal moment for both organizations, creating a synergy that positions the TSI Group for sustained success and innovation in the dynamic field of medical technology.

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
Friday, November 17, 2023
Quality, Education, Radiation, Treatment, Brain metastasis, Seed, Glioblastoma, Brain, Convention, Patient, Abstract, Caesium, Pakistan Society of Neuro-Oncology, FDA, Quality of life, Meningioma, BED, Neuro, Cancer, Metastasis, Radiosurgery, Doctor of Philosophy, Neoplasm, Use, Society, Poster, SNO, Medical physics, Medical imaging, Glioma

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.

CenSyn Secures NSF SBIR Grant and Arizona State Funding to Accelerate Commercialization of Innovative Neuro Health Medical Platform

Retrieved on: 
Thursday, November 16, 2023
NSF, Anomaly, National Science Foundation, Concussion, SBIR, Neuro, ACA, Software, Small Business Innovation Research, Health, Pharmaceutical industry

SCOTTSDALE, Ariz., Nov. 16, 2023 /PRNewswire/ -- CenSyn, a pioneering leader in the field of brain health screening technology, is thrilled to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant by the National Science Foundation (NSF). This prestigious grant is set to play a pivotal role in propelling CenSyn's groundbreaking neuro-medical platform towards early commercialization to redefine patient care in brain health management.

Key Points: 
  • This prestigious grant is set to play a pivotal role in propelling CenSyn's groundbreaking neuro-medical platform towards early commercialization to redefine patient care in brain health management.
  • The NSF SBIR Phase I grant, obtained after a highly competitive selection process, firmly underscores the remarkable potential of CenSyn's innovative neuro-medical platform in transforming how we detect concussions and manage long-term brain health.
  • "The NSF SBIR grant plays an important role in rolling out our platform for concussion screening, recovery, and long-term brain health management for diverse patient populations," said Andy Bhushan, co-founder & COO at CenSyn.
  • Alongside the NSF SBIR Phase I grant, CenSyn has secured crucial Arizona state funding, including the prestigious Arizona Commerce Authority (ACA) Arizona Innovation Challenge Grant and the backing of the WearTech applied research center.

Prevent Blindness Declares Fourth Annual Thyroid Eye Disease Awareness Week as Nov. 13-19, 2023

Retrieved on: 
Thursday, November 9, 2023
Well, UCHealth, Social media, Health, Optic nerve, Sue, Balance: Television for Living Well, Neuro, MD, Doctor of Philosophy, Inflammation, Blinking, Mental, Graves' ophthalmopathy, Visual impairment, Quality of life, Eyelid, Tissue, Immune system, TED, Paratriathlon, Autoimmune disease, Swelling, Eye, Depression, Anxiety, Therapy, Patient, Diagnosis, Communication, Mental health, Pharmaceutical industry, Nursing, Ophthalmology, Amgen

CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week." TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.

Key Points: 
  • Prevent Blindness provides free educational materials on Thyroid Eye Disease, including new Focus on Eye Health Export series episode, and debuts online art gallery from participants in the Prevent Blindness Art Therapy program
    CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared Nov. 13-19, 2023, as its fourth annual "Thyroid Eye Disease Awareness (TED) Week."
  • TED, also known as Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.
  • Because many individuals with TED are more likely to develop depression and anxiety , during TED Awareness Week, Prevent Blindness will also debut a new episode in the Focus on Eye Health Expert Series , "Thyroid Eye Disease and Mental Wellness."
  • "Now in our 4th consecutive year, we are proud to continue to educate the public and provide patients and care partners with support for Thyroid Eye Disease," said Jeff Todd, Prevent Blindness president and CEO.